CO₂ Incubator Market By Product Type (Water-Jacketed CO₂ Incubators, Air-Jacketed CO₂ Incubators, Direct Heat CO₂ Incubators, Others); By Capacity (Below 100 Liters, 100–200 Liters, Above 200 Liters); By Application (Laboratory Research and Clinical Applications, In Vitro Fertilization, Others); By Geography, Segment revenue estimation, Forecast, 2024–2032.

The co2 incubator market was worth USD 730 billion in 2023 and will be worth USD 1208.14 billion by 2030, growing at a CAGR of 6.5% during the forecast period.

 

Carbon dioxide (CO₂) incubators are specialized laboratory instruments that develop and support the necessary environmental conditions for cultivating cells, tissues, and microorganisms on culture media. These incubators control temperature, humidity, and CO₂ levels to portray physiologic conditions necessary for biochemical reactions. Most widely used in cell biology, microbiology, cancer research, or IVF, CO₂ incubators must maintain the proper conditions to avoid contamination or culture deterioration. Stem cells are crucial in sciences such as regenerative medicine, drug trialing, and stem cell science by offering a stable setting since steady conditions are needed in many surroundings.

 

Market Dynamics

One of the main forces driving the growth of the CO₂ incubator market is the rising need for cell-based therapies and regenerative medicine. The global cell therapy market size was USD 7.8 billion in 2022 and is expected to reach USD 23 billion by 2028, growing a CAGR of 19.8%. The demand increases due to stem-cell research progress and creative forms of chronic disease treatment. In these fields, it is critically important to maintain CO₂ incubators to cultivate cells and promote efficient tissue engineering. For example, in 2023, scientists at the University of California, San Francisco, created a technique of a new stem-cell therapy for Type 1 diabetes using CO₂ incubators for growing insulin-producing cells. This underlines the importance of important CO2 incubators in stimulating medical innovations and therapies.

 

A major limitation that exists in the market for CO₂ incubators is that the more sophisticated models cost between $5,000 and more than $20,000. This huge capital issue presents some challenges to other relatively small research centers and other facilities that may not be able to invest in this solution. For this reason, manufacturers are developing affordable designs and employing viable methods of financing these all-importance devices.

 

One major opportunity of the current CO₂ incubator market is to use the current and future state of technology to increase accuracy and optimize methods for CO₂ incubation for cell cultures. For instance, the incubators that are specifically developed to act as real-time monitors are useful as they enable constant tracking of culture conditions needed for cell growth. Moreover, implementing automated control systems enables temperature and optimum humidity filtration and checks and balances for CO₂ to avoid contamination and individual blunders. Newer innovations are incubators with a remote monitoring system, where the researchers can monitor the experiment from any position and make the lab practice more flexible and efficient. These technologies not only increase the certainty of experimental results but also add new areas of employment of CO₂ incubators in different scientific and medical fields.

 

Market Segmentation

Product Type:

• Water-Jacketed CO₂ Incubators

• Air-Jacketed CO₂ Incubators

• Direct Heat CO₂ Incubators

• Others

 

Capacity:

• Below 100 Liters

• 100–200 Liters

• Above 200 Liters

 

Application:

• Laboratory Research and Clinical Applications

• In Vitro Fertilization

• Others

 

End User:

• Biotechnology and Pharmaceutical Companies

• Research Institutes and Universities

• Hospitals and Medical Centers

 

By Region

North America

• US

• Mexico

• Canada

• Rest of North America

 

Europe

• Switzerland

• Russia

• France

• Germany

• U.K

• Finland

• Turkey

• Netherlands

• Belgium

• Spain

• Italy

• Rest of Europe

 

Asia Pacific

• India

• China

• South Korea

• Japan

• Singapore

• Thailand

• Indonesia

• Malaysia

• Philippines

• Australia

• Rest of Asia-Pacific

 

LAMEA

• Brazil

• Argentina

• Uruguay

• Saudi Arabia

• Rest of LAMEA

 

 

On the basis of product type, water-jacketed CO₂ incubators have been more dominant mainly because of the strength to maintain internal temperatures in the absence of a power source. But with the advancement in technology, most researchers prefer direct-heat CO₂ incubators. These incubators provide a quick rate of temperature regain and fairly even heat distribution, thus improving the cell culture. For instance, the introduction of new models of direct-heat incubators with specialized decontamination features and well-calibrated environmental regulation has made its demand high in research and clinic laboratories. These changes indicate the industry’s need for higher performance and manufacturing reliability in cell culture processes.

 

Currently, North America, especially the United States, has the largest share of the CO₂ incubator market. This leadership is due to increased spending on biotechnology and life sciences, well-developed healthcare, and production-related pharmaceutical industries. For example, NIH received over $40 billion from the U.S. government in 2023 and significantly supports biomedical research that employs CO₂ incubators. Furthermore, the region has also witnessed improvements in incubator design – for example, contamination control in the incubators and precise environmental control, which is mandatory in highly sensitive experiments. These factors combined make the region the most dominant in the market for CO₂ incubators – North America.

 

Key Players

• Thermo Fisher Scientific Inc.

• Eppendorf AG

• Memmert GmbH + Co. KG

• Sartorius AG

• PHC Holdings Corporation

• NuAire Inc.

• BINDER GmbH

• Sheldon Manufacturing Inc.

• Bellco Glass Inc.

• Benchmark Scientific Inc.

 

Recent Development

• In June 2024, Thermo Fisher Scientific will present the Thermo ScientificTM HeracellTM VIOSTM 250i AxD CO2 Incubators to facilitate future workflow automation in cell therapy production. These unique CO2 incubators aim to be integrated into automated and modular labs. The VIOS range of incubators is renowned for its low risk of contamination and ideal conditions for cell growth. The Heracell VIOS AxD CO2 incubator with patent-pending automated door control now enhances continuous cell therapy production processes by enabling robotic loading and unloading of vessels, automatically opening when integrated into a centralized lab automation platform.

 

• In October 2023, Biosan introduced the CO2 Shaker CPS-20made, especially for use in CO2 incubators, and offered controlled orbital motion of the platform. CPS-20 yields repeatable results for cell culture development and is especially intended for usage in tough settings. In addition to protecting electronics from the CO2 incubator environment, the specially-made remote controller doesn't interfere with the experiment. The ability to undertake different operations and techniques in different cultivation containers is made possible by using five interchangeable platforms.